Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline